Advanced International Journal for Research

E-ISSN: 3048-7641   •   Impact Factor: 9.11

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 7, Issue 1 (January-February 2026) Submit your research before last 3 days of February to publish your research paper in the issue of January-February.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 7 Issue 1
January-February 2026

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

Alcohol-related Hepatocellular Carcinoma in the Era of Immunotherapy: Clinical Impact of Atezolizumab Plus Bevacizumab

Author(s) LAMIA AALAOUI, Adil Debagh, Rachid Tanz, Hassan Errihani
Country Morocco
Abstract Alcohol-related liver disease has emerged as a major driver of hepatocellular carcinoma worldwide, reflecting the changing epidemiology of chronic liver disease. Hepatocellular carcinoma arising in the context of chronic alcohol exposure develops within a pro inflammatory and immunosuppressive microenvironment, raising concerns regarding responsiveness to immune based therapies. The combination of atezolizumab, a programmed death ligand 1 inhibitor, and bevacizumab, an anti vascular endothelial growth factor antibody, has become the standard first line systemic treatment for advanced hepatocellular carcinoma after demonstrating superior survival outcomes compared with sorafenib in a pivotal phase III trial. Although patients with alcohol related disease were underrepresented in randomized clinical trials, accumulating evidence from post hoc analyses and real world studies suggests that atezolizumab plus bevacizumab provides clinically meaningful benefit in alcohol related hepatocellular carcinoma, particularly in patients with preserved liver function and adequately controlled portal hypertension. This review synthesizes current evidence on the pathogenesis, immune landscape, and clinical outcomes of alcohol related hepatocellular carcinoma, with a focus on the efficacy and safety of atezolizumab plus bevacizumab and the importance of Child Pugh status in treatment selection.
Keywords Alcohol related liver disease; Alcohol related hepatocellular carcinoma; Immunotherapy; Atezolizumab; Bevacizumab; Immune checkpoint inhibitors; VEGF inhibition; Child Pugh classification; Portal hypertension.
Field Médical / Pharmacie
Published In Volume 7, Issue 1, January-February 2026
Published On 2026-02-03
View / Download PDF File

Share this



E-ISSN 3048-7641
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

AIJFR DOI prefix is
10.63363/aijfr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 7 Isu 1Cover Page Vol 6 Isu 6Cover Page Vol 6 Isu 5

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About AIJFR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9898-79-39-59 editor@aijfr.com